Do You Qualify for the Medicare GLP-1 Bridge? (Starts July 2026)

If you're on Medicare and paying full price for a GLP-1 drug, you already know the math is brutal — we're talking over a thousand dollars a month.

The good news: starting July 1, 2026, a new program called the Medicare GLP-1 Bridge could bring that cost down to around $50 a month for some Part D members.

The catch? Not everyone qualifies, not every plan participates, and it's not permanent coverage.

In this guide, you'll learn exactly who qualifies, which drugs are included, how to find out if your plan is in, and what to do if you're not eligible yet.

What Is the Medicare GLP-1 Bridge?

For years, Medicare has had a hard rule: it doesn't cover GLP-1 drugs for weight loss.

Medicare covers GLP-1s for type 2 diabetes — that coverage has always been there. But if you wanted Wegovy or Zepbound strictly for obesity, Medicare said no.

The Medicare GLP-1 Bridge changes that — at least partially and temporarily.

It's a time-bound demonstration program, not a permanent benefit. Think of it as a pilot that lets some Medicare Part D plans offer GLP-1 weight-loss coverage at a capped cost to the member.

The target price: roughly $50 per month after you've met your deductible.

Here's the deal:

This isn't Medicare suddenly covering all GLP-1s for everyone. It's a limited program with specific eligibility rules, and only certain Part D plans are participating.

But for eligible members, it is the first real path to affordable GLP-1 weight-loss coverage inside Medicare — and that's a big deal.

Which Drugs Are Covered Under the Bridge?

Not every GLP-1 on the market is included. Here's what the Medicare GLP-1 Bridge covers as of its July 2026 launch:

• Wegovy (injectable semaglutide, weekly) — FDA-approved for weight loss
• Wegovy Pill (oral semaglutide, daily) — FDA-approved for weight loss
• Zepbound (injectable tirzepatide, weekly) — FDA-approved for weight loss
• Ozempic (injectable semaglutide, weekly) — primarily a diabetes drug, included in the Bridge
• Mounjaro (injectable tirzepatide, weekly) — primarily a diabetes drug, included in the Bridge
• Foundayo (orforglipron, oral daily pill) — FDA-approved for weight loss; ~$50/mo for eligible Medicare members via the Bridge

Here's something important:

Ozempic and Mounjaro are approved for type 2 diabetes — not for weight loss. Their inclusion in the Bridge doesn't mean Medicare is now covering them for obesity in the traditional sense. If you're using them for diabetes, you likely already have Part D coverage. The Bridge is primarily the path for weight-loss-specific coverage.

Foundayo is worth calling out. It's the first oral GLP-1 pill, FDA-approved on April 1, 2026, from Eli Lilly. The self-pay price starts at $149/month — which is already lower than most GLP-1 competitors. Under the Medicare Bridge, eligible members could pay around $50/month.

Prices as of June 2026. Verify current pricing before any decision.

Who Qualifies for the Medicare GLP-1 Bridge?

This is the big question — and the answer has a few layers.

Layer 1: You Need Medicare Part D

The Bridge runs through Part D prescription drug plans, not Original Medicare (Parts A and B). You need to be enrolled in a Part D plan — either standalone or as part of a Medicare Advantage plan — to even be eligible.

Layer 2: Your Part D Plan Must Participate

This is the gatekeeping step most people miss. The Bridge is not automatic across all Part D plans. Individual plans choose whether to participate. If your plan isn't in the program, $50/month isn't on the table for you — at least not through that plan.

Layer 3: Clinical Criteria Still Apply

Just like any insurance coverage, there are likely clinical thresholds your plan will require you to meet. Based on standard prior-authorization criteria for GLP-1s, expect plans to look for:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 (overweight) with at least one weight-related condition — such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Documentation of participation in a reduced-calorie diet and increased physical activity
• A prescriber who can attest to and document each criterion in your chart

Bottom line:

You need three things to line up: Medicare Part D enrollment, a participating plan, and documented clinical eligibility. All three matter.

What About the Cardiovascular Indication for Wegovy?

This is a coverage lever worth knowing. Wegovy has an FDA indication to reduce cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight. That's a medical indication — not just a weight-loss framing — and it opens a different coverage conversation with your plan.

If you have established cardiovascular disease, make sure your prescriber documents that indication specifically. It can matter whether you're applying for the Bridge or any other coverage path.

For a deeper look at how to frame coverage requests strategically, see our guide on what to do when insurance won't cover Wegovy for weight loss.

How to Check If Your Plan Is In the Bridge

The fastest way to find out if your plan participates is to call the member services number on the back of your insurance card and ask directly: "Does my Part D plan participate in the Medicare GLP-1 Bridge demonstration program starting July 2026?"

Write down the name of the representative you spoke with and the date. That documentation matters if there's ever a dispute.

You can also:

• Check your plan's 2026 formulary update (plans are required to notify members of major changes)
• Log into your Medicare plan's member portal and search for "GLP-1" or "obesity coverage"
• Ask your prescriber's office — they often track which plans are covering specific drugs
• Check Medicare's Plan Finder tool at medicare.gov for formulary details

Here's a reality check:

Many Part D plans have historically carved out anti-obesity medications entirely. That benefit-design exclusion is the number-one reason GLP-1 coverage gets denied — and it's the reason the Bridge exists in the first place. Not every plan will flip overnight. If your plan isn't participating, you have options (more on that in the next section).

The Catch — Read This Before You Get Too Excited

We want to be straightforward with you here because this program is genuinely exciting, but it comes with real limitations.

It's a Demonstration, Not a Permanent Benefit

The Medicare GLP-1 Bridge is a time-limited demonstration program. That means it has an expiration. Demonstration programs can be extended, expanded, or ended. What starts at $50/month today is not a guarantee of $50/month indefinitely.

If you start a GLP-1 medication under the Bridge, have a plan for what happens if the program ends or your plan exits. GLP-1 drugs generally need to be taken long-term to maintain results, so a coverage gap isn't just a financial inconvenience.

Not Every Plan — And Not Every Person

We've said this above, but it bears repeating: the Bridge does not apply to all Part D plans or all Part D members. Plan participation is voluntary, and clinical criteria still apply.

The Deductible Applies First

The ~$50/month figure kicks in after your deductible. Depending on your plan's structure and where you are in the year, you may pay more until your deductible is met.

Standard Medicare Still Excludes Weight-Loss GLP-1s

Outside the Bridge program, Medicare's standard rule hasn't changed: GLP-1s for weight loss are not a covered benefit. The Bridge is a workaround — a meaningful one — but not a permanent fix to that underlying policy gap.

What If You Don't Qualify for the Bridge?

If your plan isn't participating, or you don't meet the clinical criteria, don't stop here. There are still legitimate paths to lower costs.

Cash Self-Pay Programs (No Insurance Required)

Several manufacturers offer self-pay pricing that bypasses insurance entirely. As of June 2026:

• Foundayo (orforglipron): $149/month self-pay for 1.5 mg and 4 mg doses (4 mg price holds through August 31, 2026, then moves to ~$199/month)
• Wegovy (injectable): $199/month for first 2 fills for new patients through June 30, 2026; then ~$349/month for most doses ($399 for Wegovy HD)
• Wegovy Pill (oral): $149/month self-pay for 1.5 mg and 4 mg
• Zepbound: LillyDirect self-pay vials from ~$299/month for lower doses (higher doses cost more)

These prices don't require insurance — but they have dose limits and expiration dates. Verify current pricing before you fill.

Consider Switching Plans at the Next Open Enrollment

Medicare's Annual Enrollment Period (October 15 – December 7) is your window to switch to a Part D plan that participates in the Bridge. If your current plan isn't in the program, mark your calendar and compare plans at medicare.gov next fall.

Is Diabetes or Cardiovascular Disease Documented?

GLP-1 coverage for type 2 diabetes is near-universal in Medicare Part D. If you have a diabetes diagnosis, your prescriber may be able to request coverage through that indication rather than the weight-loss pathway.

Similarly, Wegovy's cardiovascular risk reduction indication is a covered medical use — not just a weight-loss request. If cardiovascular disease is in your chart, that framing changes the coverage conversation significantly.

For a full walkthrough of how to use these leverage points, read our guide on how to get Zepbound covered by insurance in 2026.

What If You're on Medicaid?

Medicaid GLP-1 coverage for weight loss varies by state. As of 2026, 13 states are confirmed to cover it, while California, Michigan, and Pennsylvania are confirmed to be cutting that coverage. Coverage for diabetes is available nearly everywhere. Check our Medicaid coverage guide for your state's current status.

If you're navigating a denial through any insurance path, our appeal guide walks you through the full ladder — from internal appeals to external review.

The takeaway here is simple:

The Medicare GLP-1 Bridge is a major step forward, but it's not the only step. Whether you qualify for the Bridge or not, there's almost always another path worth exploring — and you don't have to navigate it alone.

Your Next Move

The Medicare GLP-1 Bridge is the first real crack in Medicare's long-standing wall against weight-loss drug coverage — and for eligible Part D members, it could cut a $1,300+ monthly bill down to about $50.

The keys: confirm your Part D plan participates, make sure your clinical documentation is tight, understand the deductible timing, and have a backup plan in case the program changes.

Which situation applies to you — are you already in a participating Part D plan, or are you waiting for open enrollment to switch? Drop your situation in the comments or use our navigator to check your options now.